ClinicalTrials.Veeva

Menu
The trial is taking place at:
M

Matrix Clinical Research | Los Angeles, CA

Veeva-enabled site

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Moderna logo

Moderna

Status and phase

Active, not recruiting
Phase 1

Conditions

Human Metapneumovirus
Respiratory Syncytial Virus

Treatments

Biological: Placebo
Biological: mRNA-1345
Drug: Nimenrix
Biological: mRNA-1365

Study type

Interventional

Funder types

Industry

Identifiers

NCT05743881
mRNA-1365-P101
2022-502022-41-00 (Other Identifier)
2022-502022-41 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to <24 months.

Enrollment

310 estimated patients

Sex

All

Ages

5 to 24 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The participant is 8 months to <24 months (Part A), 5 months to <8 months (Part B), or 8 months to <12 months (Part C) of age at the time of randomization (Day 1/Baseline visit), who is in good general health, in the opinion of the Investigator, based on review of medical history and screening physical examination.
  • In the Investigator's opinion, the parent(s)/ legally authorized representative (LAR)(s) understand and are willing and physically able to comply with protocol-mandated follow up, including all procedures, and provide written informed consent.
  • The participant is growing normally for age in the opinion of the site clinician in the months prior to enrollment.
  • The participant was born at full-term (≥37 weeks gestation) with a minimum birth weight of 2.5 kilograms (kg).
  • For Part C Cohort 7: participant must have received nirsevimab ≥6 months prior to Day 1 Visit.
  • For Part C Cohort 8: participant was eligible at any time since birth, according to national guidelines, to receive nirsevimab prior to Day 1 Visit but did not do so.

Exclusion criteria

  • Has a known history of symptomatic RSV (Part A: within 3 months; Part B and Part C: since birth) or hMPV infection (Part A: within 3 months; Part B: since birth) prior to administration of the first dose of investigational product (IP) or has a known close contact with anyone with laboratory-confirmed RSV (Parts A, B, and C) or hMPV infection (Parts A or B) within 14 days prior to administration of the first dose of IP.
  • Is acutely ill or febrile 24 hours prior to or at the screening visit. Fever is defined as a body temperature ≥38.0°Celsius/≥100.4°Fahrenheit. Participants who meet this criterion may have visits rescheduled within the relevant study visit windows.
  • Has previously been administered an investigational or approved vaccine for prevention of RSV (Parts A, B, and C) or hMPV (Parts A and B) infection or if the participant's mother received an investigational or approved vaccine for the prevention of RSV (Parts A, B, and C) or hMPV (Parts A and B) infection during pregnancy.
  • Has received investigational or approved agents for prophylaxis against RSV or hMPV (for example, monoclonal antibodies) or is intending to receive these during the course of the study. For Part C (Cohort 7 only), use of nirsevimab ≥6 months before Day 1 Visit is allowed.
  • Has a known hypersensitivity to a component of the vaccine or its excipients. Hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mRNA vaccine or any of its components (including polyethylene glycol or immediate allergic reaction of any severity to polysorbate).
  • Has a medical condition that, according to the Investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results.

Note: Other protocol-defined inclusion/exclusion criteria apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

310 participants in 10 patient groups, including a placebo group

Part A: mRNA-1345, Dose 1 (Age Group: 8 to <24 months)
Experimental group
Description:
Participants will receive mRNA-1345 vaccine by intramuscular (IM) injection on Days 1, 57 and 113.
Treatment:
Biological: mRNA-1345
Part A: mRNA-1365, Dose 1 (Age Group: 8 to <24 months)
Experimental group
Description:
Participants will receive mRNA-1365 vaccine by IM injection on Days 1, 57 and 113.
Treatment:
Biological: mRNA-1365
Part A: Placebo (Age Group: 8 to <24 months)
Placebo Comparator group
Description:
Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
Treatment:
Drug: Nimenrix
Biological: Placebo
Part B: mRNA-1345, Dose 2 (Age Group: 5 to <8 months)
Experimental group
Description:
Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
Treatment:
Biological: mRNA-1345
Part B: mRNA-1365, Dose 2 (Age Group: 5 to <8 months)
Experimental group
Description:
Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
Treatment:
Biological: mRNA-1365
Part B: mRNA-1345 Dose 1 (Age Group: 5 to <8 months)
Experimental group
Description:
Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
Treatment:
Biological: mRNA-1345
Part B: mRNA-1365 Dose 1 (Age Group: 5 to <8 months)
Experimental group
Description:
Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
Treatment:
Biological: mRNA-1365
Part B: Placebo (Age Group: 5 to <8 months)
Placebo Comparator group
Description:
Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
Treatment:
Drug: Nimenrix
Biological: Placebo
Part C: mRNA-1345 Dose 1 (Age Group 8 to <12 months exposed to nirsevimab)
Experimental group
Description:
Participants who have been previously exposed to nirsevimab will receive mRNA 1345 by IM on Days 1, 57, and 113.
Treatment:
Biological: mRNA-1345
Part C: mRNA-1345 Dose 1 (Age Group 8 to <12 months not exposed to nirsevimab)
Experimental group
Description:
Participants who have not been previously exposed to nirsevimab will receive mRNA 1345 by IM on Days 1, 57, and 113.
Treatment:
Biological: mRNA-1345

Trial contacts and locations

61

Loading...

Central trial contact

Moderna Clinical Trials Support Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems